Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Ege Akdi Ö, Aykaç K, Cengiz AB, Özsürekçi Y. Parvovirus B19 infection in children: Is it more severe than expected?. Turk J Pediatr 2024; 66: 625-629. https://doi.org/10.24953/turkjpediatr.2024.4895

References

  1. Anderson MJ, Lewis E, Kidd IM, Hall SM, Cohen BJ. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 1984; 93: 85-93. https://doi.org/10.1017/s0022172400060964
  2. Cherry JD, Schulte DJ. Human parvovirus B19. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, editors. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 8th ed. Vol 2. Philadelphia: Elsevier; 2019: 1330-1341.
  3. Serjeant GR, Topley JM, Mason K, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet 1981; 2: 595-597. https://doi.org/10.1016/s0140-6736(81)92739-2
  4. Edelson RN, Altman R. Erythema infectiosum: a statewide outbreak. J Med Soc N J 1970; 67: 805-809.
  5. Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263: 2061-2065.
  6. Gonçalves G, Correia AM, Palminha P, Rebelo de Andrade H, Alves A. Outbreaks caused by parvovirus B19 in three Portuguese schools. Euro Surveill 2005; 10: 9-10. https://doi.org/10.2807/esm.10.06.00549-en
  7. Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002; 118: 1187-1189. https://doi.org/10.1046/j.1365-2141.2002.03741.x
  8. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-459. https://doi.org/10.1046/j.1365-2141.1996.5161062.x
  9. Yango A, Morrissey P, Gohh R, Wahbeh A. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis 2002; 4: 163-166. https://doi.org/10.1034/j.1399-3062.2002.01007.x
  10. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152: 257-265. https://doi.org/10.1093/infdis/152.2.257
  11. European Centre for Disease Prevention and Control. Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. 2024. Available at: https://www.ecdc.europa.eu/en/publications-data/risks-posed-reported-increased-circulation-human-parvovirus-b19-eueea (Accessed on Jun 5, 2024).
  12. Guillet M, Bas A, Lacoste M, et al. New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023/24. Euro Surveill 2024; 29: 2400253. https://doi.org/10.2807/1560-7917.ES.2024.29.21.2400253
  13. Nordholm AC, Trier Møller F, Fischer Ravn S, et al. Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024. Euro Surveill 2024; 29: 2400299. https://doi.org/10.2807/1560-7917.ES.2024.29.24.2400299